Trials / Terminated
TerminatedNCT06530030
Goal Attainment and Physical Activity in People With Hemophilia A
Prospective, Observational Study of the Impact of Efanesoctocog Alfa (ALTUVIIIO®) on Goal Attainment and Physical Activity in People With Moderate or Severe Hemophilia A
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 3 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 12 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan. This study aims to enroll 35 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | efanesoctocog alfa | All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation. |
Timeline
- Start date
- 2024-11-26
- Primary completion
- 2025-09-18
- Completion
- 2025-09-18
- First posted
- 2024-07-31
- Last updated
- 2026-01-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06530030. Inclusion in this directory is not an endorsement.